Prelude Therapeutics Incorporated (PRLD)
PRLD Stock Price Chart
Explore Prelude Therapeutics Incorporated interactive price chart. Choose custom timeframes to analyze PRLD price movements and trends.
PRLD Company Profile
Discover essential business fundamentals and corporate details for Prelude Therapeutics Incorporated (PRLD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Sept 2020
Employees
131.00
Website
https://www.preludetx.comCEO
Krishna Vaddi
Description
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
PRLD Financial Timeline
Browse a chronological timeline of Prelude Therapeutics Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.22, while revenue estimate is $4.78m.
Earnings released on 12 May 2026
EPS came in at -$0.13 surpassing the estimated -$0.27 by +51.85%, while revenue for the quarter reached $4.58m , meeting expectations.
Earnings released on 10 Mar 2026
EPS came in at -$0.20 surpassing the estimated -$0.33 by +39.39%, while revenue for the quarter reached $5.60m , missing expectations by -72.68%.
Earnings released on 12 Nov 2025
EPS came in at -$0.26 surpassing the estimated -$0.35 by +25.71%, while revenue for the quarter reached $6.50m , missing expectations by -68.29%.
Earnings released on 14 Aug 2025
EPS came in at -$0.41 surpassing the estimated -$0.45 by +8.89%.
Earnings released on 6 May 2025
EPS came in at -$0.42 surpassing the estimated -$0.47 by +10.64%.
Earnings released on 10 Mar 2025
EPS came in at -$0.38 surpassing the estimated -$0.49 by +22.45%, while revenue for the quarter reached $4.00m .
Earnings released on 6 Nov 2024
EPS came in at -$0.43 surpassing the estimated -$0.48 by +10.42%, while revenue for the quarter reached $3.00m .
Earnings released on 12 Aug 2024
EPS came in at -$0.46 matching the estimated -$0.46.
Earnings released on 7 May 2024
EPS came in at -$0.42 surpassing the estimated -$0.47 by +10.64%.
Earnings released on 15 Feb 2024
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%, while revenue for the quarter reached $3.42m .
Earnings released on 1 Nov 2023
EPS came in at -$0.45 surpassing the estimated -$0.58 by +22.41%.
Earnings released on 3 Aug 2023
EPS came in at -$0.54 surpassing the estimated -$0.65 by +16.92%.
Earnings released on 8 May 2023
EPS came in at -$0.58 surpassing the estimated -$0.68 by +14.71%.
Earnings released on 15 Mar 2023
EPS came in at -$0.60 surpassing the estimated -$0.63 by +4.76%.
Earnings released on 14 Nov 2022
EPS came in at -$0.63 matching the estimated -$0.63.
Earnings released on 9 Aug 2022
EPS came in at -$0.58 surpassing the estimated -$0.60 by +3.33%.
Earnings released on 10 May 2022
EPS came in at -$0.63 surpassing the estimated -$0.68 by +7.35%.
Earnings released on 16 Mar 2022
EPS came in at -$0.71 falling short of the estimated -$0.69 by -2.90%.
Earnings released on 12 Nov 2021
EPS came in at -$0.66 falling short of the estimated -$0.62 by -6.45%.
Earnings released on 12 Aug 2021
EPS came in at -$0.58 falling short of the estimated -$0.51 by -13.73%.
PRLD Stock Performance
Access detailed PRLD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
